{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastro-esophageal+Cancer&page=15", "query": { "condition": "Gastro-esophageal Cancer", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 472, "total_pages": 48, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastro-esophageal+Cancer&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastro-esophageal+Cancer&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T17:34:18.836Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01285557", "title": "Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction" ], "interventions": [ { "name": "S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm)", "type": "DRUG" }, { "name": "Fluorouracil/cisplatin (control arm)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 361, "start_date": "2011-04-14", "completion_date": "2014-08-15", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-27T17:34:18.836Z", "location_count": 4, "location_summary": "Alexandria, Louisiana • Albuquerque, New Mexico • Dallas, Texas + 1 more", "locations": [ { "city": "Alexandria", "state": "Louisiana" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01285557" }, { "nct_id": "NCT02213289", "title": "PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma" ], "interventions": [ { "name": "Trastuzumab", "type": "DRUG" }, { "name": "ABT-806", "type": "DRUG" }, { "name": "Bemarituzumab", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Standard cytotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2015-01-20", "completion_date": "2020-08-20", "has_results": true, "last_update_posted_date": "2021-04-08", "last_synced_at": "2026-10-27T17:34:18.836Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02213289" }, { "nct_id": "NCT03474640", "title": "Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignancies" ], "interventions": [ { "name": "Part A", "type": "BIOLOGICAL" }, { "name": "Part B", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "TopAlliance Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 184, "start_date": "2018-02-21", "completion_date": "2022-07-07", "has_results": true, "last_update_posted_date": "2024-11-22", "last_synced_at": "2026-10-27T17:34:18.836Z", "location_count": 14, "location_summary": "Santa Monica, California • Aurora, Colorado • Miami, Florida + 9 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03474640" }, { "nct_id": "NCT05274048", "title": "Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastric Cancer", "Gastrointestinal Cancer", "HER2 Gene Mutation" ], "interventions": [ { "name": "Neratinib Pill", "type": "DRUG" }, { "name": "Fam-Trastuzumab Deruxtecan-Nxki (TDxD)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2022-06-24", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-27T17:34:18.836Z", "location_count": 3, "location_summary": "Palo Alto, California • Buffalo, New York • Philadelphia, Pennsylvania", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Buffalo", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05274048" }, { "nct_id": "NCT05400122", "title": "Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Hematologic Malignancy", "Rectum Cancer", "Acute Myeloid Leukemia", "Myelodysplastic Syndromes", "Acute Lymphoblastic Leukemia", "Chronic Myeloid Leukemia", "Chronic Lymphocytic Leukemia", "Hodgkin Lymphoma", "Non Hodgkin Lymphoma", "Myeloproliferative Syndrome", "Plasma Cell Myeloma", "Gastric Cancer", "Esophageal Cancer", "Esophagus Cancer", "Gastric Cancer, Metastatic", "Unresectable Esophageal Cancer", "Metastatic Esophageal Cancer" ], "interventions": [ { "name": "Vactosertib", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "IL-2", "type": "DRUG" }, { "name": "Natural Killer Cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David Wald", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2022-09-09", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-10-27T17:34:18.836Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05400122" }, { "nct_id": "NCT06673329", "title": "Brodalumab in the Treatment of Immune-Related Adverse Events", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Esophageal Cancer", "Kidney Cancer", "Lung Cancer", "Thyroid Cancer", "Gynecologic Cancer", "Pancreatic Cancer", "Stomach Cancer", "Brain Tumor", "Colon Cancer", "Rectal Cancer", "Head and Neck Cancer", "Oral Cancer", "Liver Cancer", "Skin Cancer", "Prostate Cancer", "Testicular Cancer", "Solid Tumor" ], "interventions": [ { "name": "Brodalumab", "type": "DRUG" }, { "name": "CT scan", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Brian Henick, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2025-03-11", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-10-27T17:34:18.836Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06673329" }, { "nct_id": "NCT01212822", "title": "Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Esophagus", "Adenocarcinoma of the Gastroesophageal Junction", "Diffuse Adenocarcinoma of the Stomach", "Intestinal Adenocarcinoma of the Stomach", "Mixed Adenocarcinoma of the Stomach", "Squamous Cell Carcinoma of the Esophagus", "Stage IA Esophageal Cancer", "Stage IA Gastric Cancer", "Stage IB Esophageal Cancer", "Stage IB Gastric Cancer", "Stage IIA Esophageal Cancer", "Stage IIA Gastric Cancer", "Stage IIB Esophageal Cancer", "Stage IIB Gastric Cancer", "Stage IIIA Esophageal Cancer", "Stage IIIA Gastric Cancer", "Stage IIIB Esophageal Cancer", "Stage IIIB Gastric Cancer", "Stage IIIC Esophageal Cancer", "Stage IIIC Gastric Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2011-04-27", "completion_date": "2018-01-03", "has_results": true, "last_update_posted_date": "2022-09-07", "last_synced_at": "2026-10-27T17:34:18.836Z", "location_count": 3, "location_summary": "Cleveland, Ohio • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01212822" }, { "nct_id": "NCT00048529", "title": "Study of T900607-Sodium in Subjects With Previously Treated Gastric Cancer or Adenocarcinoma of the Esophagus", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer", "Esophageal Neoplasms" ], "interventions": [ { "name": "T900607-sodium intravenous", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tularik", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2002-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-27T17:34:18.836Z", "location_count": 5, "location_summary": "Los Gatos, California • San Diego, California • Tampa, Florida + 2 more", "locations": [ { "city": "Los Gatos", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00048529" }, { "nct_id": "NCT07738939", "title": "IKS04 Regimen in Advanced Solid Tumors That Express CA242", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Gastro Esophageal Junctional Cancer", "Gastric Cancer (GC)", "GEJ Adenocarcinoma", "PDAC - Pancreatic Ductal Adenocarcinoma", "Biliary Tract Cancer (BTC)", "Gall Bladder Cancer", "Cholangiocarcinoma" ], "interventions": [ { "name": "IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Iksuda Therapeutics Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2026-11", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-27T17:34:18.836Z", "location_count": 4, "location_summary": "Los Angeles, California • Boston, Massachusetts • Nashville, Tennessee + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07738939" }, { "nct_id": "NCT04147494", "title": "Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Breast Carcinoma", "Colon Carcinoma", "Esophageal Carcinoma", "Gastric Carcinoma", "Head and Neck Carcinoma", "Kidney Carcinoma", "Lung Carcinoma", "Ovarian Carcinoma", "Pancreatic Carcinoma", "Solid Neoplasm", "Uterine Corpus Cancer" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Gallium Ga 68 FAPi-46", "type": "RADIATION" }, { "name": "Gallium Ga 68-labeled PSMA-11", "type": "RADIATION" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "18F-FDG", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "RADIATION" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2019-11-05", "completion_date": "2031-10-17", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-27T17:34:18.836Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04147494" } ] }